BELLICUM PHARMACEUTICALS, INC.

(BLCM)
  Report
Real-time Estimate Cboe BZX  -  12:34 2022-08-18 pm EDT
1.485 USD   -1.00%
08/11BELLICUM PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results and Provides Operational Update - Form 8-K
PU
08/11BELLICUM PHARMACEUTICALS, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/11Bellicum Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (BLCM) BELLICUM PHARMACEUTICALS Posts Q4 Revenue $500,000

03/24/2022 | 03:08pm EDT


© MT Newswires 2022
All news about BELLICUM PHARMACEUTICALS, INC.
08/11BELLICUM PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results and Provides Oper..
PU
08/11BELLICUM PHARMACEUTICALS, INC Management's Discussion and Analysis of Financial Condit..
AQ
08/11Bellicum Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
08/11Earnings Flash (BLCM) BELLICUM PHARMACEUTICALS Posts Q2 Loss $-0.13
MT
08/11Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
AQ
07/04Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
07/01Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/16BELLICUM PHARMACEUTICALS, INC : Change in Directors or Principal Officers, Submission of M..
AQ
05/16Bellicum Pharmaceuticals Files $200 Million Mixed Shelf
MT
05/12BELLICUM PHARMACEUTICALS, INC Management's Discussion and Analysis of Financial Condit..
AQ
More news
Analyst Recommendations on BELLICUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -23,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,89x
Yield 2022 -
Capitalization 12,9 M 12,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 7
Free-Float 97,5%
Chart BELLICUM PHARMACEUTICALS, INC.
Duration : Period :
Bellicum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BELLICUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,50 $
Average target price 5,00 $
Spread / Average Target 233%
EPS Revisions
Managers and Directors
Richard A. Fair President, Chief Executive Officer & Director
Jon P. Stonehouse Chairman
Joseph Howard Senesac Senior VP-Technical Operations & Quality
Jenny Chaplin Vice President-Strategic Operations
Reid M. Huber Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BELLICUM PHARMACEUTICALS, INC.0.67%13
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS37.98%76 740
REGENERON PHARMACEUTICALS, INC.0.76%68 030
WUXI APPTEC CO., LTD.-22.47%39 407
BIONTECH SE-41.02%36 949